Stock QIA QIAGEN N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Qiagen N.V. Deutsche Boerse AG

Equities

QIA

NL0015001WM6

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 04:56:33 2024-07-05 EDT 		5-day change 1st Jan Change
37.9 EUR +0.04% Intraday chart for Qiagen N.V. -1.77% -6.32%
06-27 Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50 MT
06-21 Qiagen Seeks M&A CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,655 12,018 12,618 11,355 9,910 9,003 - -
Enterprise Value (EV) 1 8,608 13,226 13,495 12,529 10,362 9,275 8,851 8,408
P/E ratio -188 x 34.5 x 25.1 x 27.1 x 30.3 x 22.4 x 19.9 x 18 x
Yield - - - - - - - -
Capitalization / Revenue 5.02 x 6.43 x 5.6 x 5.3 x 5.04 x 4.5 x 4.23 x 3.95 x
EV / Revenue 5.64 x 7.07 x 5.99 x 5.85 x 5.27 x 4.64 x 4.16 x 3.69 x
EV / EBITDA 15.6 x 17.7 x 15.3 x 15.9 x 15.7 x 12.9 x 11.3 x 9.79 x
EV / FCF 40.4 x 40.7 x 30 x 21.4 x 33.5 x 16.9 x 18.2 x 17.4 x
FCF Yield 2.47% 2.46% 3.33% 4.68% 2.99% 5.9% 5.49% 5.75%
Price to Book 3.08 x 4.31 x 4.08 x 3.28 x 2.71 x 2.39 x 2.17 x 1.97 x
Nbr of stocks (in thousands) 219,691 220,581 220,214 220,869 221,337 221,847 - -
Reference price 2 34.85 54.48 57.30 51.41 44.77 40.58 40.58 40.58
Announcement Date 20-02-04 21-02-09 22-02-08 23-02-10 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,526 1,870 2,252 2,142 1,965 2,001 2,129 2,281
EBITDA 1 551.8 747.8 884.2 789.7 659 721.4 781.8 859.2
EBIT 1 421.8 626.8 755 656.3 528.6 564.8 617.4 680.9
Operating Margin 27.63% 33.51% 33.53% 30.65% 26.9% 28.23% 29% 29.85%
Earnings before Tax (EBT) 1 -77.78 439.5 625.8 512.6 429.8 505.4 566.2 630.7
Net income 1 -41.46 359.2 512.6 423.2 341.3 402.2 444.2 507.1
Net margin -2.72% 19.2% 22.77% 19.76% 17.37% 20.1% 20.87% 22.23%
EPS 2 -0.1856 1.577 2.278 1.897 1.480 1.808 2.036 2.255
Free Cash Flow 1 212.9 325 449.1 586 309.7 547.4 485.5 483.7
FCF margin 13.95% 17.38% 19.95% 27.37% 15.76% 27.36% 22.81% 21.21%
FCF Conversion (EBITDA) 38.58% 43.46% 50.79% 74.21% 47% 75.88% 62.1% 56.3%
FCF Conversion (Net income) - 90.49% 87.61% 138.47% 90.75% 136.1% 109.31% 95.4%
Dividend per Share 2 - - - - - - - -
Announcement Date 20-02-04 21-02-09 22-02-08 23-02-10 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 582 628.4 516 500 498 485.4 494.9 475.9 509.2 458.8 494.7 503.2 533.4 488 522
EBITDA 1 231.6 266.4 178.7 175.9 168.6 157.6 168 158.2 175.3 153.3 172.4 182.9 201 170.3 183
EBIT 1 199.3 231.6 146.2 143.5 134.9 124.2 135.6 126.4 142.4 117.8 135.8 144.5 162.8 131.8 149.8
Operating Margin 34.24% 36.86% 28.33% 28.7% 27.09% 25.59% 27.4% 26.56% 27.97% 25.68% 27.45% 28.71% 30.53% 27.01% 28.7%
Earnings before Tax (EBT) - - - 95.72 - - - - - - - - - - -
Net income 1 129.2 155.3 96.66 82.39 88.84 85.04 80.79 77.82 97.66 80.67 91.8 95.74 112 - -
Net margin 22.2% 24.72% 18.73% 16.48% 17.84% 17.52% 16.33% 16.35% 19.18% 17.58% 18.56% 19.03% 21% - -
EPS 2 0.5773 0.6907 0.4330 0.3711 0.4021 0.3814 0.3608 0.3505 0.4200 0.3600 0.4400 0.4800 0.5300 0.4100 0.4700
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 22-02-08 22-04-27 22-07-26 22-11-07 23-02-10 23-05-03 23-08-08 23-10-30 24-02-06 24-04-29 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 953 1,208 876 1,174 452 273 - -
Net Cash position 1 - - - - - - 151 594
Leverage (Debt/EBITDA) 1.727 x 1.615 x 0.9912 x 1.486 x 0.6859 x 0.3782 x - -
Free Cash Flow 1 213 325 449 586 310 547 486 484
ROE (net income / shareholders' equity) 12.9% 18.9% 17.4% 12.9% 4.69% 12% 12.3% 12.1%
ROA (Net income/ Total Assets) 6.06% 9.02% 8.53% 6.81% 2.75% 7.15% 7.35% 6.97%
Assets 1 -684.1 3,982 6,008 6,217 12,403 5,625 6,040 7,277
Book Value Per Share 2 11.30 12.70 14.10 15.70 16.50 17.00 18.70 20.60
Cash Flow per Share 2 1.470 2.020 2.840 3.200 1.990 2.510 2.760 2.930
Capex 1 118 133 190 129 150 159 173 185
Capex / Sales 7.73% 7.1% 8.43% 6.03% 7.62% 7.96% 8.15% 8.13%
Announcement Date 20-02-04 21-02-09 22-02-08 23-02-10 24-02-06 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Qiagen N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
40.58 USD
Average target price
50.37 USD
Spread / Average Target
+24.12%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+16.59% 44.44B
LONZA GROUP AG Stock Lonza Group AG
+42.49% 40.03B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.62% 37.68B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.92% 31.46B
CELLTRION, INC. Stock Celltrion, Inc.
-9.23% 27.29B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.34% 26.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+41.53% 13.8B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.49% 12.46B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.40% 11.26B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. QGEN Stock
  4. QIA Stock
  5. Financials Qiagen N.V.